Rucaparib camsylate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for rucaparib camsylate and what is the scope of patent protection?
Rucaparib camsylate
is the generic ingredient in one branded drug marketed by Pharmaand and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.Rucaparib camsylate has two hundred and thirty-five patent family members in forty-three countries.
Two suppliers are listed for this compound.
Summary for rucaparib camsylate
International Patents: | 235 |
US Patents: | 9 |
Tradenames: | 1 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 31 |
Clinical Trials: | 6 |
Patent Applications: | 9 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for rucaparib camsylate |
DailyMed Link: | rucaparib camsylate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for rucaparib camsylate
Generic Entry Date for rucaparib camsylate*:
Constraining patent/regulatory exclusivity:
Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for rucaparib camsylate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Alliance for Clinical Trials in Oncology | Phase 3 |
National Cancer Institute (NCI) | Phase 3 |
Clovis Oncology, Inc. | Phase 2 |
Pharmacology for rucaparib camsylate
Drug Class | Poly(ADP-Ribose) Polymerase Inhibitor |
Mechanism of Action | Poly(ADP-Ribose) Polymerase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for rucaparib camsylate
US Patents and Regulatory Information for rucaparib camsylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 8,143,241 | ⤷ Try for Free | ⤷ Try for Free | ||||
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | ⤷ Try for Free | ⤷ Try for Free | ⤷ Try for Free | ||||
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 8,071,579 | ⤷ Try for Free | ⤷ Try for Free | ||||
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | RX | Yes | No | 10,278,974 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | RX | Yes | Yes | 8,859,562 | ⤷ Try for Free | ⤷ Try for Free | ||||
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | RX | Yes | No | 9,987,285 | ⤷ Try for Free | Y | ⤷ Try for Free | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for rucaparib camsylate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | 6,495,541 | ⤷ Try for Free |
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | 7,531,530 | ⤷ Try for Free |
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | 7,351,701 | ⤷ Try for Free |
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-001 | Dec 19, 2016 | 7,531,530 | ⤷ Try for Free |
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-003 | May 1, 2017 | 6,495,541 | ⤷ Try for Free |
Pharmaand | RUBRACA | rucaparib camsylate | TABLET;ORAL | 209115-002 | Dec 19, 2016 | 6,495,541 | ⤷ Try for Free |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for rucaparib camsylate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Australia | 2004294790 | DNA damage repair inhibitors for treatment of cancer | ⤷ Try for Free |
New Zealand | 545307 | Use of RNAI inhibiting parp activity for the manufacture of a medicament for the treatment of cancer | ⤷ Try for Free |
Spain | 2367433 | ⤷ Try for Free | |
European Patent Office | 1684736 | INHIBITEURS DE REPARATION D'ADN ENDOMMAGE POUR LE TRAITEMENT DU CANCER (DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER) | ⤷ Try for Free |
South Korea | 20060054172 | PHTHALAZINONE DERIVATIVES | ⤷ Try for Free |
Brazil | 112012019050 | sai e polimorfos de 8-fluoro-2-{metilamino)metil]fenil}-1,3,4,5-tetra-hidro-6h-azepino[5,4,3cd]indo-6-ona. | ⤷ Try for Free |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for rucaparib camsylate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1633724 | CR 2015 00012 | Denmark | ⤷ Try for Free | PRODUCT NAME: OLAPARIB, OG SALTE OG SOLVATER DERAF; REG. NO/DATE: EU/1/14/959/001 20141216 |
2534153 | SPC/GB18/043 | United Kingdom | ⤷ Try for Free | PRODUCT NAME: RUCAPARIB CAMSYLATE; REGISTERED: UK EU/1/17/1250 20180529; UK PLGB 50731/0001 20180529; UK PLGB 50731/0002 20180529; UK PLGB 50731/0003 20180529 |
2534153 | CR 2018 00041 | Denmark | ⤷ Try for Free | PRODUCT NAME: RUCAPARIB CAMSYLAT; REG. NO/DATE: EU/1/17/1250 20180529 |
1633724 | PA2015016,C1633724 | Lithuania | ⤷ Try for Free | PRODUCT NAME: OLAPARIBAS IR JO DRUSKOS IR SOLVATAI; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
2534153 | PA2018517 | Lithuania | ⤷ Try for Free | PRODUCT NAME: RUKAPARIBO KAMSILATAS; REGISTRATION NO/DATE: EU/1/17/1250 20180524 |
1633724 | 13/2015 | Austria | ⤷ Try for Free | PRODUCT NAME: OLAPARIB UND SALZE UND SOLVATE DAVON; REGISTRATION NO/DATE: EU/1/14/959 20141216 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Market Dynamics and Financial Trajectory for Rucaparib Camsylate
More… ↓
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.